HIV / AIDS in the News

Is Extended Biktarvy Exclusivity and New HIV Data Shifting Gilead's (GILD) Investment Outlook? - simplywall.st

 

ECDC: Final report from the audit of the HIV PrEP standards of care - European AIDS Treatment Group

 

New guidance from ECDC and EACS aims to raise standards of HIV care, focusing on lifelong health - European AIDS Treatment Group

 

EACS 2025: DoxyPEP cuts chlamydia and syphilis risk in men living with HIV - European AIDS Treatment Group

 

EACS 2025: Novel HIV combo therapy of lenacapavir and 2 bNAbs found effective, well tolerated in Phase 2 trial - European AIDS Treatment Group

 

EACS 2025: Investigational HIV bNAb N6LS shown safe, tolerable in Phase 2b trial - European AIDS Treatment Group

 

EACS Guidelines 2025 (version 13.0) are now available! - European AIDS Treatment Group

 

EACS 2025: People with HIV report little difference in quality of life compared with matched controls, but more depression - European AIDS Treatment Group

 

Gilead Sciences Unveils New HIV and Cancer Research Findings - StocksToTrade

 

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies - ts2.tech

 

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue? - ts2.tech

 

Would you take an HIV prevention pill if it was as easy as ordering Deliveroo? - The Independent

 

Would you take an HIV prevention pill if it was as easy as ordering Deliveroo? - the-independent.com

 

EACS 2025: Doxy-PEP Cuts Chlamydia and Syphilis Risk in Men Living With HIV - European Medical Journal

 

HIV: Campaigners call for introduction of 'game-changing' drug - BBC

 

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results - Yahoo

 

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results - Yahoo Finance

 

Amazing People of 2025: Javier Muñoz - hivplusmag.com

 

N6LS bNAb HIV Treatment - Infectious Disease Special Edition

 

HIVMA HIV Research IDWeek 2025 Anna Person - Infectious Disease Special Edition

 

Study Finds Patients Prefer 1 HIV Long-Acting Injectable Due to Fewer Injection Site Reactions - Infectious Disease Special Edition

 

European standards of HIV prevention and care: Module on Commencement of antiretroviral therapy - European Centre for Disease Prevention and Control

 

Doravirine Islatravir HIV Treatment - Infectious Disease Special Edition

 

Cutaneous Squamous Cell Carcinoma Mimicking Kaposi Sarcoma in an HIV-Positive Patient: Diagnostic Challenges and Therapeutic Response to Liposomal Doxorubicin - Cureus

 

Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in Phase 2 Trial - Infectious Disease Special Edition

 

From HIV to Global Cancer Prevention: A New Chapter in Global Health Financing - amfAR, The Foundation for AIDS Research

 

Gilead Sciences: HIV Treatments Propel Stocks - StocksToTrade

 

An injection to prevent HIV is something to celebrate - The Observer

 

UK's NICE Recommends ViiV Healthcare’s Injectable HIV Treatment - GSK (NYSE:GSK) - Benzinga

 

NICE recommends HIV prevention injection for people unable to take oral PrEP - The Pharmaceutical Journal